Eli Lilly & Company

Type: Company
Name: Eli Lilly & Company (Eli Lilly and Company)
First reported 3 hours ago - Updated 26 mins ago - 4 reports

FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes

The US Food and Drug Administration (FDA) has approved dulaglutide ( Trulicity , Eli Lilly & Co), as a once-weekly injection for the treatment of type 2 diabetes.A member of the glucagon-like peptide-1 receptor agonist class, dulaglutide joins liraglutide ... [Published Diabetes Care - 26 mins ago]
First reported 12 hours ago - Updated 1 hour ago - 2 reports

Lilly's Phase III Trial Of Cyramza With Paclitaxel Meets Endpoints

Eli Lilly and Co. (LLY: Quote) Thursday said its Phase III trial of ramucirumab or Cyramza in combination with paclitaxel in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma met primary and secondary endpoints. Paclitaxel, ... [Published RTTNews.com - 11 hours ago]
First reported 10 hours ago - Updated 2 hours ago - 3 reports

INSIDE INDIANA BUSINESS: Elanco, Dow Agro announce partnership

Two of the biggest players in the state's biotechnology industry are joining forces. Greenfield-based Elanco, the animal health division of Eli Lilly and Co., and Dow AgroSciences LLC in Indianapolis have reached a research and development agreement. ... [Published NWI Times - 2 hours ago]
First reported 12 hours ago - Updated 3 hours ago - 2 reports

Put a lid on 'Low-T' drug use, FDA panel advises, threatening AbbVie, Lilly meds

The testosterone-drug party may be over. An FDA advisory panel wants to limit their use for safety reasons--and the proposed restrictions would shrink sales significantly. That's not good news for AbbVie ($ABBV), the market leader, and other drugmakers ... [Published FiercePharma - 8 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Lilly Cancer Treatment Reaches Primary Endpoint

A potential cancer treatment being developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) continues to move forward. The pharmaceutical maker reports a late-stage trial shows patients taking Cyramza in combination with another drug had a "statistically ... [Published Inside INdiana Business - 8 hours ago]
First reported 16 hours ago - Updated 11 hours ago - 2 reports

Denovo Biopharma acquires oncology drug from Eli Lilly

Singapore: Denovo Biopharma has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly.Lilly developed enzastaurin in a variety of indications, including in Phase 2 and Phase 3 clinical trials for diffuse large B-cell lymphoma (DLBCL). In studies ... [Published Bio Spectrum Asia - 11 hours ago]
First reported 16 hours ago - Updated 16 hours ago - 1 reports

Eli Lilly v Human Genome Sciences Ltd

UK High Court denies Eli Lilly’s request to prevent Human Genome Sciences Ltd from obtaining a Supplementary Protection Certificate for the human monoclonal antibody, tabalumab.SummaryIn a judgment dated 18 July 20141, the UK High Court refused to grant ... [Published Lexology - 16 hours ago]
First reported Sep 17 2014 - Updated 16 hours ago - 3 reports

AstraZeneca, Eli Lilly ink agreement for AZD3293 for Alzheimer’s disease

AstraZeneca  and  Eli Lilly have inked an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.The progression of Alzheimer’s ... [Published Center Watch - 16 hours ago]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Lilly joins in on development of AZ's BACE inhibitor; companies to co-promote

Related Biotechnology, Pharmaceutical and Healthcare NewsEli Lilly & Co. will lead development activities for AstraZeneca PLC’s oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293, which completed Phase I trials for Alzheimer’s disease.Original ... [Published BioPortfolio - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 2 reports

'The Daily Show' Wants to Rap to You About Drugs

Comedy CentralThe Daily Show just wants to have an open and honest conversation with you about drugs. Everything's going to be okay. Jon Stewart and his team are here for you. And by "you," they mean "millions of Americans [suffering] side effects too ... [Published The Atlantic Wire - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 2 reports

Denovo Biopharma buys late-stage oncology drug for development as personalized medicine

Biotechnology company Denovo Biopharma revealed on Tuesday the completion of the acquisition of the late-stage oncology drug enzastaurin from Eli Lilly and Company (NYSE:LLY) for an undisclosed amount. This acquisition grants Denovo with all rights to ... [Published Individual.com - Sep 17 2014]
Entities: DeNovo, Oncology, Drugs
First reported Sep 17 2014 - Updated Sep 17 2014 - 2 reports

Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis

Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular ... [Published Pettinga Financial Advisors - Sep 17 2014]

Quotes

...David Kendall, vice president, medical affairs, Lilly Diabetes. "Trulicity is a new, non-insulin, injectable option that was designed with the patient in mind. It will be available in a once-weekly pen and does not require mixing, measuring nor needle handling."
...oncology, hematology with the Center for Palliative Care at Kliniken Essen-Mitte in Germany, and principal investigator of the RAINBOW trial. "Currently, there is a significant need for effective therapies to help combat this deadly disease and ramucirumab in this combination could provide a valuable second-line treatment option."
"Type 2 diabetes is a serious chronic condition that causes blood glucose levels to rise higher than normal,” said Mary Parks, M D , deputy director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “Trulicity is a new treatment option, which can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of type 2 diabetes.”"
"In this way, Bayer would position itself as a world-leading company in the field of human, animal and plant health" the company said, adding that it would float MaterialScience within the next 12-18 months

More Content

All (1806) | News (1237) | Reports (0) | Blogs (516) | Audio/Video (0) | Fact Sheets (18) | Press Releases (31)
sort by: Date | Relevance
FDA Approves Once-Weekly Dulaglutide for Type 2... [Published Diabetes Care - 26 mins ago]
Looking to commercialise insulin Glargine by 20... [Published FirstWord Pharma - 1 hour ago]
FDA approves dulaglutide to treat type 2 diabetes [Published Orthopedics Today - 2 hours ago]
Lilly's Type 2 Diabetes Drug Trulicity Gets FDA... [Published Nasdaq - 2 hours ago]
FDA Approves Trulicity™ (dulaglutide), Lilly's ... [Published PR Newswire - 2 hours ago]
Bayer Takeover of Zoetis in Reach After Plastic... [Published Washington Post - 2 hours ago]
INSIDE INDIANA BUSINESS: Elanco, Dow Agro annou... [Published NWI Times - 2 hours ago]
FDA Approves Trulicity(TM) (dulaglutide), Lilly... [Published Scottrade - 2 hours ago]
Lilly's Type 2 Diabetes Drug Trulicity Gets FDA... [Published 4 Traders - 2 hours ago]
Bingham ediscovery news - summer 2014 [Published Lexology - 2 hours ago]
Lilly's Combo Treatment Improves OS in Gastric ... [Published Drug Discovery and Development - 2 hours ago]
Sibu Beauty Adds Robert A. King as CEO [Published American Spa - 3 hours ago]
Elanco Animal Health, Dow AgroSciences LLC Anno... [Published BioSpace - 3 hours ago]
FDA approves Trulicity to treat type 2 diabetes [Published U.S. Food and Drug Administration - 3 hours ago]
Ramucirumab/Paclitaxel Improves Survival in Sec... [Published PT Community - 3 hours ago]
Lilly's Type 2 Diabetes Drug Trulicity Gets FDA... [Published 4 Traders - 3 hours ago]
Ocera Therapeutics Announces Appointment of Ste... [Published Nation's Restaurant News - 4 hours ago]
Bayer hits record high on move to list plastics... [Published Yahoo! News South Africa - 6 hours ago]
Five things for pharma marketers to know: Thu... [Published Medical Marketing And Media - 6 hours ago]
TRANSLATE-ACS: No MACE Benefit With Prasugrel i... [Published American Journal of Public Health - 6 hours ago]
FDA backs ED upstart Stendra as a fast-acting a... [Published FiercePharma - 6 hours ago]
State Invites Comments From Duke Customers [Published Inside INdiana Business - 7 hours ago]
Lilly Cancer Treatment Reaches Primary Endpoint [Published Inside INdiana Business - 8 hours ago]
Put a lid on 'Low-T' drug use, FDA panel advise... [Published FiercePharma - 8 hours ago]
PETE THE PLANNER: Rich advice [Published Insurance News Net - 9 hours ago]
A safe bet? [Published Insurance News Net - 9 hours ago]
FDA committees near-unanimous on need to invest... [Published Orthopedics Today - 9 hours ago]
Elanco Animal Health, Dow AgroSciences announce... [Published Feedstuffs - 9 hours ago]
Stock Update (NYSE:LLY): Elanco Animal Health, ... [Published Crawford Financial Planning - 9 hours ago]
Gilead Sciences: The Recent Dip In Share Price ... [Published Seeking Alpha - 9 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Eli Lilly (LLY) Showing Bullish Technicals [Published MarketIntelligenceCenter.com - 12 hours ago]
For a hedged play on Eli Lilly and Co (LLY) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a Nov. '14 $67.50 covered call for a net debit in the $65.11 area. That is also the break-even stock price for the covered call. This ...
CYRAMZA™ In Combination With Paclitaxel Signifi... [Published PR Newswire: Entertainment & Media - 12 hours ago]
INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results of the global Phase III trial of ramucirumab (CYRAMZA™) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or ...
Colorescience completes $15 mln Series B prefer... [Published PE Hub Blog - Sep 17 2014]
Colorescience has closed a $15 million Series B preferred stock offering at $1.14 per share. Longwood Fund led the round. Also, the company has named Rich Aldrich of Longwood Fund to its board of directors. Headquartered in Carlsbad, Calif., Colorescience ...
Astra Zeneca and Eli Lilly Teaming Up for Alzhe... [Published Partnerships in Clinical Trials - Sep 17 2014]
There are over 44 million suffering from Alzheimer's Disease, and two big Pharma companies just teamed up to find a cure for the disease.  Eli Lilly and Astra Zeneca joined forces to develop a drug that would possibly bring in $5 billion in revenue, ...
Eli Lilly (LLY) Trading Near $64.53 Support Level [Published MarketIntelligenceCenter.com - Sep 17 2014]
A covered call identified by MarketIntelligececenter.com's patented algorithms on Eli Lilly and Co (LLY) could yield about 4.09% (22.60% annualized, for comparison purposes only) in 66 days. Pair a long position in the stock with the Nov. '14 $67.50 call ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Lilly and AstraZeneca announce alliance to co-d... [Published Financial Services - Sep 16 2014]
AZ AND LILLY ALLIANCE TO DEVELOP BACE INHIBITOR [Published GlobeNewswire: Advertising News - Sep 16 2014]
AstraZeneca and Lilly announce alliance to deve... [Published AstraZeneca - Sep 16 2014]
Trial Results, Notes Exchange Offer, Consortium... [Published Financial Services - Sep 11 2014]
Biotech Advancements in Innovative Cancer Thera... [Published Financial Services - Sep 04 2014]
1 2 3 4 5 6 7
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.